Information policy
In accordance with Art. 38 of the Articles of Association (on medmix.swiss/en/Investors/Governance; under Downloads), the official means of publication of medmix Ltd is the Swiss Official Journal of Commerce. Notices to registered shareholders may, at the election of the Board of Directors, be validly given by publication in the Swiss Official Journal of Commerce or in a form that can be evidenced by text.
medmix Ltd reports on its financial results every half year. It also comments on business performance and outlook. In addition, the company reports on price-related facts on an ongoing basis (ad hoc publications). The reporting referred to in the compensation report (including the respective references to the financial reporting section) complies with the recommendations on the content of the compensation report as laid out in section 42 of Appendix 1 to the Swiss Code of Best Practice for Corporate Governance.
The address of medmix' main registered office is Neuhofstrasse 20, 6340 Baar, Switzerland.
Key dates in 2024
- February 22: Annual results 2023 and annual results webcast
- April 24: Annual Shareholders` Meeting 2024
- July 18: Mid-year results 2024
These dates and any changes can be viewed on medmix.swiss/en/Investors/Financial-Reports. Media releases sent via e-mail, including ad hoc disclosures, can be subscribed to on https://www.medmix.swiss/news/media-release-subscription or viewed at medmix' website under [https://www.medmix.swiss/News]. Further information is available on medmix.swiss, or by contacting Investor Relations at investorrelations@medmix.com.
The contact address for Investor Relations is:
medmix Ltd
Investor Relations
Neuhofstrasse 20
6340 Baar
Switzerland
+41417237375
Investorrelations@medmix.com
Black-out periods
Generally and regardless of whether any inside information exists or not, pursuant to medmix’ Securities Trading, Public Disclosure, and Reporting Regulations, the trading in medmix Ltd securities is prohibited for (a) the members of the Board of Directors and the Executive Committee, (b) any staff reporting to any member of the Executive Committee that has access to inside information, (c) members of Group Finance, Group Planning and M&A, Group Communications and Investor Relations, and any relevant staff with access to inside information as well as the members of the medmix management group, and (d) any external advisor having access to inside information in connection with medmix Ltd’s financial reporting during the following periods: the periods starting on January 1 and July 1 up to and including the trading day of the public releases of the respective full-year or half-year reports (if published prior to 7:30 am CET) or the following trading day (if published between 5:40 pm and midnight CET).
Under certain circumstances (in particular, in case of personal hardship), the company may allow exceptions to a black-out period upon reasoned request by an employee, provided that such employee is not in possession of any inside information. Such exceptions must be issued in writing with a copy to the employee’s file.